Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Pediatric Acute Leukemias (AML/ALL) KOL Interview

    $599.00

    Highlights Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients. CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications. Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely […]

    April 1, 2015
    Find out more

  • Pneumococcal Vaccines KOL Interview

    $599.00

    Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

    August 27, 2016
    Find out more

  • Multiple Sclerosis KOL Insight Interview

    $599.00

    Multiple Sclerosis KOL Insight Interview

    October 28, 2014
    Find out more

  • Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

    $599.00

    The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

    October 30, 2020
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview

    Atopic Dermatitis and Psoriasis KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more
  • Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

    Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

    $599.00

    An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.

    March 17, 2022
    Find out more

  • 2015 Cancer Drug Pricing Surveys

    $799.00

    We performed two 5-question surveys of oncologists in the US to gauge the impact of cancer treatment costs on prescribed therapies.

    August 10, 2015
    Find out more

  • Acne Prescribing Practices Pulse Survey

    $599.00

    We performed a survey of 10 dermatologists currently practicing in the US to gauge

    prescribing practices for the treatment of acne.

    November 29, 2016
    Find out more

  • Palbociclib for Breast Cancer

    $89.00

    Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

    February 1, 2014
    Find out more

  • 2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview

    $599.00

    Following our live coverage of ASH, we interviewed a KOL who specializes in treating lymphoid malignancies to provide further insight on current and future paradigms for the treatment of CLL and NHLs.

    January 28, 2015
    Find out more

  • Datamonitor Healthcare HIV KOL Interview – Germany

    $599.00

    A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

    January 25, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – UK

    $599.00

    A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Ebola KOL Interview #1

    $599.00

    So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.

    November 2, 2014
    Find out more

  • Post-AASLD US KOL Interview

    $599.00

    Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.

    December 16, 2014
    Find out more

  • Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

    $599.00

    This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.

    February 6, 2019
    Find out more

  • Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

    June 30, 2020
    Find out more
  • 2015-cll-pulse-2-drug-usage-and-reimbursement

    2015 Chronic Lymphocytic Leukemia (CLL) Pulse

    $599.00

    We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.

    January 27, 2015
    Find out more

  • Schizophrenia and Bipolar Disorder Payer Interview – US, South

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.

    April 28, 2021
    Find out more
  • Chronic Neuropathic Pain Survey

    Chronic Neuropathic Pain KOL Survey

    $599.00

    Biomedtracker performed a 5-question survey of 30 United States neurologists who currently treat patients with chronic neuropathic pain and prescribe opioids to at least some of their patients with chronic neuropathic pain to gauge current use of adjuvants (TCAs, anti-convulsants, SNRIs, SSRIs, and NMDA receptor antagonists) and potential future use of cebranopadol and raxatrigine to treat chronic neuropathic pain.

    March 9, 2017
    Find out more

  • Ovarian Cancer KOL Interview – US, East Coast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

    April 1, 2020
    Find out more

  • Dyslipidemia KOL Insight Interview #2

    $599.00

    Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.

    July 28, 2014
    Find out more
  • Abuse-Deterrent Opioids Survey

    Abuse-Deterrent Opioids Survey KOL Interview

    $599.00

    Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.

    March 9, 2017
    Find out more

  • Datamonitor Schizophrenia KOL Interview 2

    $599.00

    KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

    February 24, 2016
    Find out more

  • 2015 Breast Cancer Pulse #2

    $599.00

    This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.

    May 26, 2015
    Find out more

  • Intersection Between Tech and Pharma KOL Interview

    $599.00

    Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

    January 12, 2016
    Find out more

  • 2015 Jardiance EMPA-REG CVOT Pulse

    $599.00

    This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).

    November 1, 2015
    Find out more

  • Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

    $599.00

    A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

    January 8, 2019
    Find out more

  • Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Midwest

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

    June 30, 2020
    Find out more

  • Datamonitor Healthcare Multiple Myeloma KOL Interview – UK

    $599.00

    This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.

    January 18, 2019
    Find out more
  • Topic: Colorectal Cancer (CRC)

    Colorectal Cancer KOL Interview – UK

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.

    May 23, 2022
    Find out more

  • Acute Lymphocytic Leukemia KOL Interview

    $599.00

    [Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

    February 9, 2016
    Find out more
  • Opioids and Chronic Neuropathic Pain Management KOL Interview

    Opioids and Chronic Neuropathic Pain Management KOL Interview

    $599.00

    Biomedtracker interviewed a neurologist based in the United States who currently treats over 1000 patients with chronic neuropathic pain per year to determine his current treatment practices for indications including fibromyalgia and views on the use of opioids and abuse-deterrent opioids.

    March 9, 2017
    Find out more

  • Alzheimer’s Disease KOL Interview – US, Northeast

    $599.00

    This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

    January 28, 2019
    Find out more

  • Triple Negative Breast Cancer KOL Interview

    $599.00

    “It [Abraxane] is so easy to give. Women tolerate it so well. It works pretty good, it doesn’t work all the time, it works pretty well, and the patients don’t get so fatigued, they don’t have side effects, they don’t need premeds, and they rarely need to be boosted for white cells decrease. Whereas in the Eribulin, you know they’re gonna be coming back. It’s a pretty easy drug to give. Patients tolerate it fairly well… I use it [Abraxane] as first line and I go back to it. Even if I have somebody that progresses, if they’ve been off of it for a while, I will often even go back to it.”

    February 9, 2016
    Find out more

  • Multiple Sclerosis (MS) KOL Interview – UK, London

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • NASH KOL Insight Interview #2

    $599.00

    KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]

    March 4, 2014
    Find out more

  • Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

    April 28, 2021
    Find out more

  • NASH KOL Insight Interview #1

    $599.00

    The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold

    February 20, 2014
    Find out more

  • 2014 Community-Acquired Pneumonia Pulse

    $599.00

    We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates.

    December 18, 2014
    Find out more

  • Asthma and COPD KOL Interview

    $599.00

    KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

    February 29, 2016
    Find out more

  • Dermatology KOL Interview

    $599.00

    BioMedTracker – Dermatology KOL Interview                                                                                                                           In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

    October 31, 2014
    Find out more

  • Datamonitor Axial Spondyloarthritis KOL Interviews

    $599.00

    Datamonitor interviewed three arthritis specialists, one based each in France, Italy and the US, to gauge their views on currently available treatment options, pipeline drugs, biosimilars and treatment challenges in axial spondyloarthritis (axSpA). The three interviews were combined into a single report.

    March 9, 2017
    Find out more

  • Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

    $599.00

    An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.

    November 19, 2018
    Find out more

  • Multiple Myeloma KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

    May 15, 2020
    Find out more

  • Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

    $599.00

    Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.

    May 13, 2014
    Find out more
Page 1 of 5
Page 1 of 512345
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top